altretamine has been researched along with Disease Exacerbation in 2 studies
Altretamine: A hexamethyl-2,4,6-triamine derivative of 1,3,5-triazine.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A number of active agents in ovarian cancer (platinum, paclitaxel, topotecan, liposomal doxorubicin, docetaxel, gemcitabine, and etoposide) will be reviewed in the context of what is known about cumulative toxicity, potential adverse effects on patients' quality of life, and evidence addressing the potential benefits of longer-term treatment." | 2.42 | Recurrent ovarian cancer: how important is it to treat to disease progression? ( Herzog, TJ, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Herzog, TJ | 1 |
| Markman, M | 1 |
| Liu, PY | 1 |
| Rothenberg, ML | 1 |
| Monk, BJ | 1 |
| Brady, M | 1 |
| Alberts, DS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase III Randomized Trial of 12 Months vs. 3 Months of Paclitaxel in Patients With Advanced Ovarian Cancer Who Attain a Clinically Defined Complete Response (CR) Following Platinum/Paclitaxel-Based Chemotherapy[NCT00003120] | Phase 3 | 308 participants (Actual) | Interventional | 1997-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for altretamine and Disease Exacerbation
| Article | Year |
|---|---|
Recurrent ovarian cancer: how important is it to treat to disease progression?
Topics: Altretamine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cis | 2004 |
1 other study available for altretamine and Disease Exacerbation
| Article | Year |
|---|---|
Pretreatment CA-125 and risk of relapse in advanced ovarian cancer.
Topics: Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Disease Progressi | 2006 |